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Schizophrenia is a complex disorder involving dysregulation of
multiple pathways in its pathophysiology with strong evidence
to support roles for dopaminergic, glutamatergic, GABAergic,
and cholinergic neurotransmitter systems and their interactions
in the pathophysiology of the disorder (Benes, 2009; Karam
et al., 2010; Gibbons et al., 2013). Additionally, evidence from
genetic, post-mortem and animal studies over the past decade
has identified a number of susceptibility factors for schizophre-
nia, including neuregulin 1 (Nrg1) and its receptor ErbB4,
disrupted-in-schizophrenia-1 (DISK1), catechol-O-methyl trans-
ferase (COMT), BDNF, and Akt, along with their related path-
ways, that interact closely with dopaminergic, glutamatergic, and
GABAergic neurotransmitter systems (Karam et al., 2010). Hence
a key question is how these neurotransmitter systems and their
interactions contribute to the pathophysiology of schizophre-
nia and whether interactive changes in these pathways occur in
early brain development, based on the view of schizophrenia as a
developmental disorder?
This Frontier Research Topic has brought together leading
experts in the field to address these questions from different
angles in nine reviews, one theoretic article and two research
articles. The first four articles focus on the roles and interac-
tions of neurotransmitters in the pathophysiology of psychiatric
disorders. Snyder and Gao (2013) provide an excellent review
of NMDA receptor hypofunction hypothesis, suggesting NMDA
receptor hypofunction as a convergence point for progression
and symptoms of schizophrenia. They also discuss evidence on
altered NMDA receptor subunits in schizophrenia and how these
alterations interact with multiple schizophrenia susceptibility
genes that lead to NMDA receptor dysfunction during devel-
opment (Snyder and Gao, 2013). Scarr et al. (2013) present an
in depth and very detailed coverage of cholinergic involvement
in schizophrenia and how it interacts with other neurotrans-
mitters including glutamate, dopamine, GABA and serotonin,
as well as its links with the inflammatory/immune system. The
review also provides a frame work for testable hypotheses of
the potential outcomes of a dysregulated cholinergic system for
research into the pathophysiologies of psychiatric disorders (Scarr
et al., 2013). Cognitive deficits are considered core symptoms of
schizophrenia, while abnormalities in gamma oscillations have
been identified in schizophrenia patients that are associated with
deficits in attention, working memory, and other cognitive func-
tions (Uhlhaas and Singer, 2010). Furth et al. (2013) reviewed the
central role of dopamine D4 receptor in the generation of gamma
frequency synchronization of neural networks and cognitive pro-
cesses via their influence on parvalbumin-expressing GABAergic
interneurons. They also examined their close synergistic rela-
tionship with neuregulin/ErbB4 signaling, in particular in the
prefrontal cortex and hippocampus two major brain regions
implicated in schizophrenia (Furth et al., 2013). Furthermore,
there has been increasing evidence linking oxidative stress to the
pathophysiology of schizophrenia. In their article, Yao and his
team reviewed some of these findings, focusing particularly on
their findings on homeostatic imbalance of purine catabolism and
its association withmonoamine neurotransmitters in first episode
antipsychotic-naïve patients with schizophrenia (Yao et al., 2013).
In the following three papers, Chana et al. have provided an
excellent review of the current progress in the search for biomark-
ers for schizophrenia and psychosis, focusing on biomarkers for
major neurotransmitter systems in post-mortem brain studies, as
well as covering some recent and exciting studies in microRNA
dysregulation in both the blood and brain of schizophrenia
patients (Chana et al., 2013). It is followed by a very timely
review of current knowledge on the features of polysialic acid
and their synthesizing enzymes (specially ST8SIA2), their func-
tions in regulations of cell adhesion, ion channels, neurotrophins
(such as BDNF) and catecholamine neurotransmitters (partic-
ularly dopamine), in light of several recent lines of evidence
linking polysialic acid to schizophrenia (Sato and Kitajima, 2013).
Iwakura and Nawa provide a very clear overview of the ErbB1-
4 dependent EGF/neuregulin signals, their role in regulating the
development and function of the central nervous system, and the
contribution of deficits in ErbB signaling to schizophrenia and
neurological disease (Iwakura and Nawa, 2013).
Four articles discuss the animal model of schizophrenia, two
of which address the Nrg1-cannabinoid interaction in a hypo-
morphic Nrg1 (Nrg1 HET) mouse model of schizophrenia. In
an original study, Spencer et al. investigated Nrg1-cannabinoid
interaction in the hippocampus using proteomics, in which
they identified alterations of some proteins involved in vesicu-
lar release of neurotransmitters, serotonergic neurotransmission,
and growth factor release in response toNrg1 hypomorphism and
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Nrg1-cannabinoid interaction (Spencer et al., 2013). In a short
review, Karl and Arnold further discussed the complex neuro-
behavioral effects ofNrg1-cannabinoid interaction and its clinical
implications (Karl and Arnold, 2013). In a BDNF heterozygous
mouse model, Manning and van den Buuse investigated the
effects of chronic methamphetamine treatment during late ado-
lescence/early adulthood on a behavioral endophenotype related
to the positive symptoms of schizophrenia, prepulse inhibition
(PPI) of the acoustic startle reflex (Manning and van den Buuse,
2013). In the fourth animal model paper, altered dopamine
ontogeny in the developmentally vitamin D deficient rat model
and its relevance to schizophrenia were reviewed (Kesby et al.,
2013). This review suggests that early alterations in dopamine
ontogeny are a core feature in the pathophysiology of schizophre-
nia representing a critical aspect useful to a model of this disease.
Finally, in the context of schizophrenia as a neurodevelop-
mental disorder, Catts et al. (2013) discuss elegantly the normal
development of the prefrontal cortex on the molecular and cellu-
lar levels in line with cognitive development, as well as the timing
of cognitive decline in schizophrenia. They proposed to recon-
sider schizophrenia as an outcome from a failure to reach the final
state of cortical maturation resulting in retainment of an imma-
ture cortex rather than resulting from an excess of adolescent
synaptic pruning (Catts et al., 2013).
In summary, these studies illustrate clearly the interactive
nature of specific pathways on different levels of the brain from
molecular and cellular pathways, and neural circuits to functional
deficits contributing to the pathophysiology of schizophrenia. We
believe that this Frontier Research Topic will stimulate the devel-
opment of future collaborative and interdisciplinary research to
reveal the unknown mechanisms underlying the pathophysiology
of schizophrenia.
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